Explore By Subject Area   
Return Home
Register Here Menu

Immuno-Oncology 360°

Date: Feb 10, 2026 - Feb 12, 2026

Location: Boston, MA

Day Three: Thursday, February 12, 2026
Showing Events in 1 Track from 08:00am to 08:40am
Opening Keynote & Morning Session
General Session: Grand Ballroom / 1:1 Partnering Meetings: Back Bay AB
8:00AM - 8:30AM
1:1 Partnering Meetings
8:30AM - 8:40AM
Day Three Welcome
Chair:
Daniel S Chen, MD, PhD, Founder & CEO, Synthetic Design Lab, Inc
Showing Events in 1 Track from 08:40am to 10:20am
IO Clinical Advancements Plenary
Grand Ballroom
8:40AM - 9:00AM
Keynote: Beyond the Breakthrough: Evolving Insights and Next Steps from the Landmark Dostarlimab Trial
Speaker:
Andrea Cercek, Physician-Scientist & Medical Oncologist; Section Head of Colorectal Cancer; Founder and co-director of the Center for Young Onset Colorectal and Gastrointestinal Cancer, Memorial Sloan Kettering Cancer Center
9:00AM - 9:20AM
Zeitgeist: IO 2.0 Multifunctional Antibodies
Speaker:
Axel Hoos, MD, PhD, Former CEO, Scorpion Therapeutics
9:20AM - 9:40AM
Redefining Maintenance Therapy in Small Cell Lung Cancer: Clinical Progress from the IMforte Trial
Speaker:
Amal Melhem-Bertrandt, MD, Therapeutic Area Head, Oncology Clinical Development, Jazz Pharmaceuticals
9:40AM - 10:20AM
Panel Discussion: Next-Generation Bispecifics in IO
Moderator:
Asthika Goonewardene, MBA, Managing Director, Senior Biotech Analyst, Truist Securities
Fireside Guests:
Roy Baynes, MD, PhD, EVP & CMO, Eikon Therapeutics
Daniel S Chen, MD, PhD, Founder & CEO, Synthetic Design Lab, Inc
Shubh Goel, VP, Global Franchise Head (OBU), Bispecifics, AstraZeneca
Showing Events in 1 Track from 10:20am to 11:00am
Morning IO360º Breakfast, Networking, Exhibits & 1:1 Partnering Meetings
Networking & Exhibits: Grand Ballroom Foyer / 1:1 Partnering Meetings: Back Bay AB
10:20AM - 11:00AM
IO360° Networking Break
Showing Events in 1 Track from 11:00am to 12:20pm
IO Clinical Advancements Plenary Continued
Grand Ballroom
11:00AM - 11:20AM
Cytokines Reinvigorated: Overview of the New IL-2 Landscape and Introduction to STK-012
Speaker:
Naiyer Rizvi, MD, CMO, Synthekine
11:20AM - 11:40AM
Clinical Update on IBI363: A PD-1/IL-2 Bispecific Antibody Fusion Protein in Melanoma
Speakers:
Samuel Zhang, PhD, MBA, Global CBO, Innovent Biologics
11:40AM - 12:00PM
Cadonilimab in Cervical Cancer: Registration Data from China’s PD-1/CTLA-4 Bispecific
12:00PM - 12:20PM
Clinical update on GV20-0251: an AI-discovered, first-in-class immunotherapy against IGSF8
Speaker:
Ying Gong, PhD, CBO, GV20
Showing Events in 1 Track from 12:20pm to 01:20pm
Lunch
1:1 Partnering Meetings: Back Bay AB
12:20PM - 1:20PM
Lunch on Own & 1:1 Partnering Meetings
Showing Events in 1 Track from 01:20pm to 02:35pm
IO Clinical Advancements Plenary (Continued)
Grand Ballroom
1:20PM - 1:40PM
IN8bio's Unique DeltEx Drug Resistant Immunotherapy (DRI) Approach to Solid Tumors & Results from Phase 1/2 Study in Newly Diagnosed GBM
Speaker:
William Ho, MBA, President & CEO, IN8Bio
1:40PM - 1:55PM
Lytix's Novel Oncolytic Peptides and Small Molecules: Enhancing Neoadjuvant I/O Efficacy Across Solid Tumors
Speaker:
Brent Meadows, CBO, Lytix Biopharma
1:55PM - 2:15PM
Trispecific Antibodies Redefining Myeloma Therapy: Clinical Insights from J&J 5322
Speaker:
Sangmin Lee, MD, Executive Medical Director, Early Development Hematology, J&J Innovative Medicine
2:15PM - 2:35PM
Perioperative Immunotherapy in HNSCC: New Standards with Neoadjuvant and Adjuvant Keytruda
Speaker:
Bin Zhao, MD, PhD, Scientific Associate Vice President & Section Head, Thoracic Oncology and Product Development, Merck Research Laboratories
Showing Events in 1 Track from 03:00pm to 03:00pm
End of Conference
3:00PM - 3:00PM
End of Conference
Next
Day Three
Thursday, February 12, 2026

Subscribe for More Information

Please provide your contact information and select areas of interest to receive updates.